PMID- 29630732
OWN - NLM
STAT- MEDLINE
DCOM- 20190930
LR  - 20220408
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 88
IP  - 6
DP  - 2018 Jun
TI  - Impact of cross-sex hormone therapy on bone mineral density and body composition 
      in transwomen.
PG  - 856-862
LID - 10.1111/cen.13607 [doi]
AB  - OBJECTIVE: Cross-sex hormone therapy (CSHT) has been associated with changes in 
      bone and lean/fat mass. This study assessed bone mineral density (BMD), 
      appendicular lean mass (ALM), and total fat mass in transwomen undergoing CSHT. 
      PATIENTS AND DESIGN: We evaluated 142 transwomen (mean age: 33.7 +/- 10.3 years; 
      BMI: 25.4 +/- 4.6; 86.6% with previous CSHT) during the first 3 months of regular 
      oestrogen treatment (with or without anti-androgens). A reference group including 
      22 men and 17 cis women was also studied. MEASUREMENTS: Clinical and hormonal 
      evaluation and dual-energy X-ray absorptiometry (DXA). RESULTS: Bone mineral 
      density was similar in trans and reference women, and lower at all sites in 
      transwomen vs men. Low bone mass for age was observed in 18% of transwomen at 
      baseline vs none of the reference women or men. Appendicular lean mass and total 
      fat mass were positively correlated with L1-L4 BMD, explaining 14.9% of the 
      observed variation in lumbar spine BMD and 20.6% of the variation in total femur 
      BMD. Appendicular lean mass was similar in trans and reference women, and lower 
      in transwomen vs men. Total fat mass was lower in trans vs reference women. 
      Densitometry was repeated after a mean of 31.3 +/- 6.5 months in 46 transwomen. 
      There was a significant increase in total fat mass and a significant decrease in 
      ALM. Bone mineral density remained stable over time. CONCLUSIONS: The fairly high 
      prevalence of low bone mass in this sample of transwomen from southern Brazil 
      seems to be related to lower ALM. Non-pharmacological lifestyle-related 
      strategies for preventing bone loss could be beneficial for transgender women 
      receiving long-term CSHT.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Fighera, Tayane Muniz
AU  - Fighera TM
AD  - Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clinicas 
      de Porto Alegre, Porto Alegre, Brazil.
AD  - Gender Identity Program, Hospital de Clinicas de Porto Alegre, Porto Alegre, 
      Brazil.
FAU - da Silva, Eliane
AU  - da Silva E
AD  - Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clinicas 
      de Porto Alegre, Porto Alegre, Brazil.
AD  - Gender Identity Program, Hospital de Clinicas de Porto Alegre, Porto Alegre, 
      Brazil.
FAU - Lindenau, Juliana Dal-Ri
AU  - Lindenau JD
AD  - Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clinicas 
      de Porto Alegre, Porto Alegre, Brazil.
FAU - Spritzer, Poli Mara
AU  - Spritzer PM
AUID- ORCID: 0000-0002-6734-7688
AD  - Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clinicas 
      de Porto Alegre, Porto Alegre, Brazil.
AD  - Gender Identity Program, Hospital de Clinicas de Porto Alegre, Porto Alegre, 
      Brazil.
AD  - Department of Physiology, Federal University of Rio Grande do Sul, Porto Alegre, 
      Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180424
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Estrogens)
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Absorptiometry, Photon
MH  - Adolescent
MH  - Adult
MH  - Body Composition/*drug effects/physiology
MH  - Body Mass Index
MH  - Bone Density/*drug effects/physiology
MH  - Brazil
MH  - Estradiol/therapeutic use
MH  - Estrogens/therapeutic use
MH  - Female
MH  - Humans
MH  - Linear Models
MH  - Male
MH  - Transsexualism/*drug therapy
MH  - Young Adult
OTO - NOTNLM
OT  - bone mineral density
OT  - cross-sex hormone treatment
OT  - dual-energy X-ray absorptiometry
OT  - fat mass
OT  - lean mass
OT  - transsexualism
EDAT- 2018/04/10 06:00
MHDA- 2019/10/01 06:00
CRDT- 2018/04/10 06:00
PHST- 2018/01/30 00:00 [received]
PHST- 2018/03/25 00:00 [revised]
PHST- 2018/03/26 00:00 [accepted]
PHST- 2018/04/10 06:00 [pubmed]
PHST- 2019/10/01 06:00 [medline]
PHST- 2018/04/10 06:00 [entrez]
AID - 10.1111/cen.13607 [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2018 Jun;88(6):856-862. doi: 10.1111/cen.13607. Epub 2018 
      Apr 24.